BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $234
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris has maintained an 'Outperform' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY), but lowered the price target from $250 to $234.
October 10, 2023 | 1:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alnylam Pharmaceuticals' price target has been lowered from $250 to $234 by BMO Capital, though the 'Outperform' rating is maintained.
The lowering of the price target by BMO Capital could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100